May 25, 2018 09:59 AM EDTUpdated May 26, 08:22 PM

CRI report tracks explosive growth of cell therapies in the global pipeline, as China researchers muscle toward the front

John Carroll

Editor & Founder

The Cancer Research Institute is shining a light on the explosive growth of cell therapies in the clinic, spotlighting China’s virtual overnight success in grabbing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CRI report tracks explosive growth of cell therapies in the global pipeline, as China researchers muscle toward the front

John Carroll

Editor & Founder

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Bristol Myers sues the federal government over 340B, following other drugmakers

CRI re­port tracks ex­plo­sive growth of cell ther­a­pies in the glob­al pipeline, as Chi­na re­searchers mus­cle to­ward the front

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

CRI report tracks explosive growth of cell therapies in the global pipeline, as China researchers muscle toward the front

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Bristol Myers sues the federal government over 340B, following other drugmakers